Case Report
Abstract
The introduction of targeted therapies has offered the promise of better survival outcomes for patients with metastatic renal cell carcinoma. Sunitinib malate, an oral, multitargeted tyrosine kinase inhibitor, is an important treatment option for patients with metastatic renal cell carcinoma. This case study explores the controversial use of sunitinib in a patient with a non-clear cell variant of renal cell carcinoma, also on treatment with combined antiretroviral treatment for a co-existing human immunodeficiency virus infection.
Key words: Sunitinib, non-clear cell metastatic renal cell carcinoma, human immunodeficiency virus and antiretroviral treatment.
Copyright © 2025 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0